Loading
Cancer of lymphocytes, the white blood cells of the immune system, usually growing as masses in lymph nodes, spleen or other organs. It is divided into Hodgkin lymphoma and the non-Hodgkin lymphomas, most of which arise from B cells and keep surface markers such as CD20 that antibodies, ADCs and CAR-T can target.
Most lymphomas arise from B cells and keep surface markers such as CD19, CD20 and CD30, which has made them the proving ground for antibody therapy (rituximab, 1997), ADCs (brentuximab vedotin), CAR-T (axicabtagene, 2017) and bispecific T-cell engagers (glofitamab); diffuse large B-cell lymphoma is the commonest type and is often curable with chemo-immunotherapy. Hodgkin lymphoma, defined by its Reed-Sternberg cells, is highly curable and exceptionally responsive to PD-1 blockade. Lymphomas and leukaemias overlap: the same malignant lymphocyte can present as a mass (lymphoma) or circulate in the blood (leukaemia).
In plain words · CD19 is a marker on B cells and B-cell cancers, and was the target of the first CAR-T therapies ever approved.
Showing the target this term concerns: CD19.
Shares B-cell, T-cell and NK-cell lymphoma, Indolent and aggressive lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma).
Shares B-cell, T-cell and NK-cell lymphoma, Nodal and extranodal lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Brentuximab vedotin.
Shares Indolent and aggressive lymphoma, Nodal and extranodal lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Mycosis fungoides.
Shares Indolent and aggressive lymphoma, Nodal and extranodal lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Mycosis fungoides.
Shares Indolent and aggressive lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), CD20, Hodgkin lymphoma.
Shares B-cell, T-cell and NK-cell lymphoma, Nodal and extranodal lymphoma, The two lymphoma classifications of 2022 (WHO-HAEM5 and ICC), Diffuse large B-cell lymphoma.
Shares Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Chronic lymphocytic leukaemia, Hodgkin lymphoma.
Shares Burkitt lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Chronic lymphocytic leukaemia, Hodgkin lymphoma.